Medicare Part D copays are set to rise on branded drugs

11/21/2011 | Sioux City Journal (Iowa)

Out-of-pocket costs that Medicare Part D enrollees will pay next year for brand-name drugs will rise by an average of 40% for preferred drugs and 30% for nonpreferred drugs, according to an Avalere Health study. Copays for nonpreferred generic drugs will drop by about 43% and will stay about the same for preferred generics, the study found.

View Full Article in:

Sioux City Journal (Iowa)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT